Is Buying TRANSGENE S.A. ORDINARY SHARES (OTCMKTS:TRGNF), Having Lower Short Interest a Winning Strategy?

October 13, 2018 - By Peter Erickson

Transgene SA (OTCMKTS:TRGNF) Logo

The stock of TRANSGENE S.A. ORDINARY SHARES (OTCMKTS:TRGNF) registered a decrease of 50% in short interest. TRGNF’s total short interest was 100 shares in October as published by FINRA. Its down 50% from 200 shares, reported previously. With 100 shares average volume, it will take short sellers 1 days to cover their TRGNF’s short positions.

It closed at $3.49 lastly. It is down 0.00% since October 13, 2017 and is . It has underperformed by 15.62% the S&P500.

Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company has market cap of $208.82 million. The company??s lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of metastatic non-small cell lung cancer; and Pexa-Vec, an oncolytic virus primarily for the treatment of liver cancer. It currently has negative earnings. The Company’s products in the clinical development stage also comprise TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus; TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder.

Another recent and important Transgene SA (OTCMKTS:TRGNF) news was published by which published an article titled: “Transgene updates on pipeline” on September 19, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News